Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Mallinckrodt
Julphar
Fuji
Boehringer Ingelheim
McKinsey
Citi
Queensland Health
Teva
Johnson and Johnson

Generated: October 23, 2017

DrugPatentWatch Database Preview

Gd Searle Company Profile

« Back to Dashboard

What is the competitive landscape for GD SEARLE, and what generic alternatives to GD SEARLE drugs are available?

GD SEARLE has forty-six approved drugs.

There are eight US patents protecting GD SEARLE drugs.

There are ninety-four patent family members on GD SEARLE drugs in thirty countries and thirty-five supplementary protection certificates in ten countries.

Summary for Applicant: Gd Searle

International Patents:94
US Patents:8
Tradenames:41
Ingredients:29
NDAs:46
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Gd Searle Llc
NORQUEST FE
ethinyl estradiol; ferrous fumarate; norethindrone
TABLET;ORAL-28018926-001Jul 18, 1986DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
CALAN
verapamil hydrochloride
TABLET;ORAL018817-004Feb 23, 1988DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
ENOVID
mestranol; norethynodrel
TABLET;ORAL010976-008Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
POTASSIUM CHLORIDE
potassium chloride
INJECTABLE;INJECTION086219-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-002Dec 31, 1998ABRXYesNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
NORPACE CR
disopyramide phosphate
CAPSULE, EXTENDED RELEASE;ORAL018655-001Jul 20, 1982RXYesNo► Subscribe► Subscribe► Subscribe
Gd Searle
DAYPRO
oxaprozin
TABLET;ORAL018841-004Oct 29, 1992ABRXYesYes► Subscribe► Subscribe► Subscribe
Gd Searle Llc
INSPRA
eplerenone
TABLET;ORAL021437-003Sep 27, 2002DISCNNoNo► Subscribe► SubscribeY► Subscribe
Gd Searle Llc
NORPACE
disopyramide phosphate
CAPSULE;ORAL017447-001Approved Prior to Jan 1, 1982ABRXYesNo► Subscribe► Subscribe► Subscribe
Gd Searle Llc
ENOVID
mestranol; norethynodrel
TABLET;ORAL-20010976-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Gd Searle

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-003Aug 29, 2002► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
CU-7
copper
INTRAUTERINE DEVICE;INTRAUTERINE017408-001Approved Prior to Jan 1, 1982► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
ARTHROTEC
diclofenac sodium; misoprostol
TABLET, DELAYED RELEASE;ORAL020607-002Dec 24, 1997► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-001Feb 26, 1996► Subscribe► Subscribe
Gd Searle
CELEBREX
celecoxib
CAPSULE;ORAL020998-002Dec 31, 1998► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
Gd Searle Llc
COVERA-HS
verapamil hydrochloride
TABLET, EXTENDED RELEASE;ORAL020552-002Feb 26, 1996► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for GD SEARLE drugs

Drugname Dosage Strength Tradename Submissiondate
diclofenac sodium and misoprostol
Delayed-release Tablets50 mg/0.2 mg
ARTHROTEC
6/29/2009
diclofenac sodium and misoprostol
Delayed-release Tablets75 mg/0.2 mg
ARTHROTEC
11/28/2008
celecoxib
Capsules50 mg
CELEBREX
3/21/2008
eplerenone
Tablets25 mg and 50 mg
INSPRA
9/27/2006

Non-Orange Book Patents for Gd Searle

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,534,089 Uniform drug delivery therapy► Subscribe
6,863,902 Immediate release eplerenone compositions► Subscribe
6,592,902 Controlled release eplerenone compositions► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Gd Searle Drugs

Country Document Number Estimated Expiration
Israel143301► Subscribe
World Intellectual Property Organization (WIPO)9737640► Subscribe
Eurasian Patent Organization004064► Subscribe
TaiwanI234459► Subscribe
Spain2166988► Subscribe
World Intellectual Property Organization (WIPO)0051642► Subscribe
Spain2250803► Subscribe
South Korea20000005230► Subscribe
South Africa200107779► Subscribe
MexicoPA01009035► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Gd Searle Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0055France► SubscribePRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C0009Belgium► SubscribePRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015
0443983/03Switzerland► SubscribePRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
04C/008Belgium► SubscribePRODUCT NAME: EPLERENONE; NATIONAL REGISTRATION NO/DATE: 241 IS 188 F3 20041220; FIRST REGISTRATION: NL RVG 29963 20040316
156Luxembourg► SubscribePRODUCT NAME: LEVONORGESTREL ET ETHINYLESTRADIOL; FIRST REGISTRATION DATE: 20150211
00128Netherlands► SubscribePRODUCT NAME: VALDECOXIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH ACCEPTABEL ZOUT; REGISTRATION NO/DATE: EU/1/02/239/001 - EU/1/02/239/024, EU/1/02/242/001 - EU/1/02/242/024, EU/1/02/244/001 - EU/1/02/244/024 20030317
12/008Ireland► SubscribePRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209
2011 00026Denmark► SubscribePRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216
00221Netherlands► SubscribePRODUCT NAME: DROSPIRENON EN ETHINYLESTRADIOL; REGISTRATION NO/DATE: RVG 23827 20000307
1214076/01Switzerland► SubscribePRODUCT NAME: DROSPIRENONE + ETHINYLESTRADIOL; REGISTRATION NUMBER/DATE: SWISSMEDIC 57946 13.06.2008
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
AstraZeneca
Cipla
Chubb
Teva
Dow
Covington
Novartis
Deloitte
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot